Adma Biologics (ADMA) Cash from Investing Activities (2011 - 2025)

Adma Biologics has reported Cash from Investing Activities for 13 years, with the latest figure at -$276000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Investing Activities rose 89.96% year-over-year to -$276000.0; the trailing twelve-month figure through Dec 2025 stood at -$21.9 million (down 155.29% YoY), and the FY2025 full-year result was -$21.9 million, down 155.29% from the prior year.
• Cash from Investing Activities for Q4 2025 stood at -$276000.0, up from -$14.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was -$276000.0 in Q4 2025, with the low at -$14.4 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$3.1 million across 5 years, with a median of -$2.7 million in 2021.
• The largest YoY upside for Cash from Investing Activities was 89.96% in 2025 against a maximum downside of 1208.56% in 2025.
• Adma Biologics' Cash from Investing Activities stood at -$3.7 million in 2021, then retreated by 1.98% to -$3.7 million in 2022, then surged by 62.46% to -$1.4 million in 2023, then slumped by 95.45% to -$2.8 million in 2024, then surged by 89.96% to -$276000.0 in 2025.
• The last three Cash from Investing Activities figures came in at -$276000.0 (Q4 2025), -$14.4 million (Q3 2025), and -$2.5 million (Q2 2025), per Business Quant data.